Literature DB >> 11325827

Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells.

E Ackerstaff1, B R Pflug, J B Nelson, Z M Bhujwalla.   

Abstract

In this study, a panel of normal human prostate cells (HPCs) and tumor cells derived from metastases were studied by (1)H NMR spectroscopy to determine whether the malignant transformation of HPCs results in the elevation of choline compounds. Although an elevated choline signal has been observed previously in clinical studies, the contribution of the different Cho compounds to this elevation, as well as their quantification, has not been established until now. Here we have shown that HPCs derived from metastases exhibit significantly higher phosphocholine as well as glycerophosphocholine levels compared with normal prostate epithelial and stromal cells. Thus the elevation of the choline peak observed clinically in prostate cancer is attributable to an alteration of phospholipid metabolism and not simply to increased cell density, doubling time, or other nonspecific effects. Androgen deprivation of the androgen receptor-positive cell lines resulted in a significant increase of choline compounds after chronic androgen deprivation of the LNCaP cell line and in a decrease of choline compounds after a more acute androgen deprivation of the LAPC-4 cell line. These data strongly support the use of proton magnetic resonance spectroscopic imaging to detect the presence of prostate cancer for diagnosis, to detect response subsequent to androgen ablation therapy, and to detect recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325827

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  107 in total

1.  Total choline at 1H-MRS and [18F]-fluoromethylcholine uptake at PET.

Authors:  Sandi Kwee; Thomas Ernst
Journal:  Mol Imaging Biol       Date:  2010-08       Impact factor: 3.488

2.  Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.

Authors:  Fatma Al-Saeedi
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

3.  Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.

Authors:  Egidio Iorio; Alessandro Ricci; Marina Bagnoli; Maria Elena Pisanu; Giancarlo Castellano; Massimo Di Vito; Elisa Venturini; Kristine Glunde; Zaver M Bhujwalla; Delia Mezzanzanica; Silvana Canevari; Franca Podo
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  PET/CT imaging of recurrent prostate cancer.

Authors:  B Scher; M Seitz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

5.  Molecular Imaging in Breast Cancer - Potential Future Aspects.

Authors:  Katja Pinker; Wolfgang Bogner; Stephan Gruber; Peter Brader; Siegfried Trattnig; Georgios Karanikas; Thomas H Helbich
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

6.  Live-cell vibrational imaging of choline metabolites by stimulated Raman scattering coupled with isotope-based metabolic labeling.

Authors:  Fanghao Hu; Lu Wei; Chaogu Zheng; Yihui Shen; Wei Min
Journal:  Analyst       Date:  2014-05-21       Impact factor: 4.616

7.  Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts.

Authors:  Hanna M Romanska; Stefano Tiziani; Rachael C Howe; Ulrich L Günther; Zulfiqar Gulzar; El-Nasir Lalani
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 8.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

9.  [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Vincenzo Scattoni; Valentino Bettinardi; Cesare Cozzarini; Massimo Freschi; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-16       Impact factor: 9.236

10.  Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.

Authors:  H Carl Le; Mihaela Lupu; Khushali Kotedia; Neal Rosen; David Solit; Jason A Koutcher
Journal:  Magn Reson Med       Date:  2009-11       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.